Go Pro
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free BCAB Stock Alerts

BioAtla (BCAB) Financials

BioAtla logo
$3.82 -0.13 (-3.19%)
As of 12:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BioAtla

Annual Income Statements for BioAtla

This table shows BioAtla's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.65 -72 -95 -106 -123 -70 -60
Consolidated Net Income / (Loss)		 -30 -36 -95 -106 -123 -70 -60
Net Income / (Loss) Continuing Operations		 -31 -72 -95 -106 -123 -70 -60
Total Pre-Tax Income 		-31 -36 -95 -106 -123 -70 -60
Total Operating Income		 -28 -30 -96 -108 -130 -74 -59
Total Gross Profit		 5.20 0.43 0.25 0.00 0.00 11 2.00
Total Revenue		 5.20 0.43 0.25 0.00 0.00 11 2.00
Operating Revenue		 5.20 0.43 0.25 0.00 0.00 11 2.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 33 31 97 108 130 85 61
Selling, General & Admin Expense		 7.55 11 38 29 26 22 18
Research & Development Expense		 26 20 58 79 104 63 44
Total Other Income / (Expense), net		 -3.17 -5.75 1.04 1.66 6.23 4.17 -0.30
Interest & Investment Income		 0.13 0.10 0.35 1.65 6.31 3.37 0.84
Other Income / (Expense), net		 -1.67 -1.58 0.00 0.01 -0.09 0.80 -1.15
Other Gains / (Losses), net		 - -36 - - - - -0.30
Basic Earnings per Share		 ($0.53) ($3.19) ($2.76) ($2.74) ($2.58) ($1.44) ($1.01)
Weighted Average Basic Shares Outstanding		 0.00 8.43M 34.56M 38.93M 47.78M 48.57M 58.83M
Diluted Earnings per Share		 ($0.53) ($3.19) ($2.76) ($2.74) ($2.58) ($1.44) ($1.01)
Weighted Average Diluted Shares Outstanding		 0.00 8.43M 34.56M 38.93M 47.78M 48.57M 58.83M
Weighted Average Basic & Diluted Shares Outstanding		 54.60M 8.43M 34.56M 47.61M 48.10M 58.40M 82.85M

Quarterly Income Statements for BioAtla

This table shows BioAtla's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -33 -27 -23 -21 -11 -15 -15 -19 -16 -9.78 -6.34
Consolidated Net Income / (Loss)		 -33 -27 -23 -21 -11 -15 -15 -19 -16 -9.78 -6.34
Net Income / (Loss) Continuing Operations		 -33 -27 -23 -21 -11 -15 -15 -19 -16 -10 -6.31
Total Pre-Tax Income 		-33 -27 -23 -21 -11 -15 -15 -19 -16 -9.79 -6.31
Total Operating Income		 -35 -29 -24 -22 -11 -16 -18 -19 -14 -9.26 -9.31
Total Gross Profit		 0.00 - 0.00 0.00 11 - 0.00 0.00 0.00 2.00 0.00
Total Revenue		 0.00 - 0.00 0.00 11 - 0.00 0.00 0.00 2.00 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 35 29 24 22 22 16 18 19 14 11 9.33
Selling, General & Admin Expense		 6.62 5.86 5.61 5.77 5.88 4.59 5.26 4.96 4.25 3.26 4.75
Research & Development Expense		 28 23 19 16 16 12 12 14 9.54 8.00 4.58
Total Other Income / (Expense), net		 1.70 1.61 1.22 0.90 0.68 1.36 2.28 -0.06 -1.99 -0.53 3.00
Interest & Investment Income		 1.73 1.64 1.22 0.90 0.69 0.55 0.40 0.23 0.13 0.08 0.04
Other Income / (Expense), net		 -0.04 -0.03 0.00 0.00 -0.01 0.81 1.88 -0.30 -2.12 -0.61 2.96
Basic Earnings per Share		 ($0.70) ($0.55) ($0.48) ($0.44) ($0.22) ($0.30) ($13.16) ($0.32) ($0.27) ($0.16) ($4.22)
Weighted Average Basic Shares Outstanding		 47.83M 47.78M 48.09M 48.21M 48.34M 48.57M 1.16M 58.50M 58.75M 58.83M 1.50M
Diluted Earnings per Share		 ($0.70) ($0.55) ($0.48) ($0.44) ($0.22) ($0.30) ($13.16) ($0.32) ($0.27) ($0.16) ($4.22)
Weighted Average Diluted Shares Outstanding		 47.83M 47.78M 48.09M 48.21M 48.34M 48.57M 1.16M 58.50M 58.75M 58.83M 1.50M
Weighted Average Basic & Diluted Shares Outstanding		 47.94M 48.10M 48.12M 48.34M 48.35M 58.40M 58.42M 58.72M 58.79M 82.85M 1.66M

Annual Cash Flow Statements for BioAtla

This table details how cash moves in and out of BioAtla's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -7.16 235 6.37 -29 -104 -62 -42
Net Cash From Operating Activities		 -9.65 -36 -62 -90 -104 -72 -48
Net Cash From Continuing Operating Activities		 -9.65 -36 -62 -90 -104 -72 -48
Net Income / (Loss) Continuing Operations		 -30 -36 -95 -106 -123 -70 -60
Consolidated Net Income / (Loss)		 -30 -36 -95 -106 -123 -70 -60
Depreciation Expense		 0.86 1.01 1.33 1.20 1.22 0.93 0.37
Non-Cash Adjustments To Reconcile Net Income		 -5.98 1.16 24 15 14 8.11 6.75
Changes in Operating Assets and Liabilities, net		 25 -2.65 7.43 0.29 4.68 -11 4.28
Net Cash From Investing Activities		 -1.51 -0.59 -0.92 -0.27 -0.10 0.00 0.00
Net Cash From Continuing Investing Activities		 -1.51 -0.59 -0.92 -0.27 -0.10 0.00 0.00
Net Cash From Financing Activities		 4.00 272 70 61 0.08 9.51 6.28
Net Cash From Continuing Financing Activities		 4.00 272 70 61 0.08 9.51 6.28
Repayment of Debt		 - - - - 0.00 0.00 -0.90
Issuance of Debt		 4.00 3.43 0.00 - - 0.00 0.00
Issuance of Common Equity		 0.00 200 71 62 0.34 9.56 0.10
Other Financing Activities, net		 0.00 0.00 0.14 -0.76 -0.26 -0.05 7.07

Quarterly Cash Flow Statements for BioAtla

This table details how cash moves in and out of BioAtla's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -27 -30 -31 -19 -5.15 -7.47 -17 -14 -9.89 -1.20 -5.16
Net Cash From Operating Activities		 -27 -30 -31 -19 -5.13 -17 -16 -14 -9.88 -7.92 -5.27
Net Cash From Continuing Operating Activities		 -27 -30 -31 -19 -5.13 -17 -16 -14 -9.88 -7.92 -5.27
Net Income / (Loss) Continuing Operations		 -33 -27 -23 -21 -11 -15 -15 -19 -16 -9.78 -6.34
Consolidated Net Income / (Loss)		 -33 -27 -23 -21 -11 -15 -15 -19 -16 -9.78 -6.34
Depreciation Expense		 0.27 0.37 0.24 0.23 0.23 0.23 0.18 0.12 0.06 0.02 0.12
Non-Cash Adjustments To Reconcile Net Income		 3.52 2.74 2.30 2.50 2.19 1.12 -0.24 1.67 3.41 1.90 -1.88
Changes in Operating Assets and Liabilities, net		 2.19 -6.11 -10 -0.85 3.03 -3.25 -0.90 2.80 2.43 -0.05 2.83
Net Cash From Investing Activities		 -0.03 -0.01 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -0.03 -0.01 0.00 - - - 0.00 - - - 0.00
Purchase of Property, Plant & Equipment		 -0.03 -0.01 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -0.04 0.12 -0.01 0.23 -0.01 9.31 -0.40 -0.04 -0.01 6.71 0.11
Net Cash From Continuing Financing Activities		 -0.04 0.12 -0.01 0.23 -0.01 9.31 -0.40 -0.04 -0.01 6.71 0.11
Repayment of Debt		 - - 0.00 - - - -0.37 -0.08 - -0.45 -0.29
Issuance of Common Equity		 0.01 0.15 - - - 9.31 0.00 - - 0.05 0.41
Other Financing Activities, net		 -0.06 -0.03 -0.01 -0.02 -0.01 - -0.03 -0.01 -0.01 7.11 -0.01

Annual Balance Sheets for BioAtla

This table presents BioAtla's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 245 254 226 120 52 14
Total Current Assets		 241 247 220 116 51 8.01
Cash & Equivalents		 239 245 216 111 49 7.12
Prepaid Expenses		 2.08 2.31 4.92 4.94 2.19 0.90
Plant, Property, & Equipment, net		 4.10 3.68 2.73 1.60 0.68 0.12
Total Noncurrent Assets		 0.15 3.45 2.58 1.65 0.51 5.70
Other Noncurrent Operating Assets		 0.15 3.45 2.58 1.65 0.51 5.70
Total Liabilities & Shareholders' Equity		 245 254 226 120 52 14
Total Liabilities		 35 44 45 49 38 50
Total Current Liabilities		 32 20 23 28 15 22
Accounts Payable		 12 18 22 27 14 16
Other Current Liabilities		 - 1.39 1.52 1.62 0.84 5.57
Total Noncurrent Liabilities		 2.70 24 22 21 24 28
Other Noncurrent Operating Liabilities		 0.01 24 22 21 24 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 210 211 180 71 14 -36
Total Preferred & Common Equity		 210 211 180 71 14 -36
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 210 211 180 71 14 -36
Common Stock		 301 397 473 487 500 509
Retained Earnings		 -91 -186 -293 -416 -486 -546

Quarterly Balance Sheets for BioAtla

This table presents BioAtla's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 151 89 69 62 38 27 16 8.57
Total Current Assets		 148 86 66 61 38 21 9.67 3.09
Cash & Equivalents		 141 81 62 57 32 18 8.32 1.96
Prepaid Expenses		 6.23 5.80 4.83 4.05 5.17 2.41 1.35 1.13
Plant, Property, & Equipment, net		 1.97 1.36 1.13 0.91 0.50 0.38 0.32 0.00
Total Noncurrent Assets		 1.89 1.41 1.01 0.76 0.26 6.14 5.91 5.47
Other Noncurrent Operating Assets		 1.89 1.41 1.01 0.76 0.26 6.14 5.91 5.47
Total Liabilities & Shareholders' Equity		 151 89 69 62 38 27 16 8.57
Total Liabilities		 57 39 37 39 38 44 47 46
Total Current Liabilities		 36 19 17 19 16 17 18 21
Accounts Payable		 34 18 16 18 15 16 17 19
Other Current Liabilities		 1.60 1.51 1.66 1.25 0.55 0.81 1.17 1.56
Total Noncurrent Liabilities		 21 20 20 20 22 27 29 25
Other Noncurrent Operating Liabilities		 21 20 20 20 22 27 29 25
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 95 50 31 23 0.55 -17 -31 -37
Total Preferred & Common Equity		 95 50 31 23 0.55 -17 -31 -37
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 95 50 31 23 0.55 -17 -31 -37
Common Stock		 484 489 492 494 502 503 505 515
Retained Earnings		 -389 -439 -461 -471 -501 -520 -536 -552

Annual Metrics And Ratios for BioAtla

This table displays calculated financial ratios and metrics derived from BioAtla's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 36,835,849.00 37,607,297.00 47,935,808.00 - 58,792,088.00
DEI Adjusted Shares Outstanding		 0.00 0.00 36,835,849.00 37,607,297.00 47,935,808.00 - 1,175,842.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -2.59 -2.83 -2.58 - -50.69
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -91.75% -41.72% -100.00% 0.00% 0.00% -81.82%
EBITDA Growth		 0.00% -5.48% -210.07% -12.43% -20.22% 43.82% 16.81%
EBIT Growth		 0.00% -5.82% -204.41% -12.12% -20.02% 43.64% 17.36%
NOPAT Growth		 0.00% -6.48% -220.41% -12.13% -19.93% 42.98% 19.80%
Net Income Growth		 0.00% -20.09% -166.09% -11.61% -15.95% 43.48% 14.57%
EPS Growth		 0.00% -501.89% 13.48% 0.72% 5.84% 44.19% 29.86%
Operating Cash Flow Growth		 0.00% -276.71% -71.23% -45.34% -15.04% 30.84% 32.99%
Free Cash Flow Firm Growth		 0.00% 0.00% -991.01% -21.84% -14.01% 32.15% 42.91%
Invested Capital Growth		 0.00% 0.00% -22.22% -2.96% -16.01% 14.75% -24.51%
Revenue Q/Q Growth		 0.00% 0.00% -37.50% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -26.20% -4.39% 0.26% 15.24% 8.20%
EBIT Q/Q Growth		 0.00% 0.00% -25.78% -4.32% 0.20% 15.21% 8.44%
NOPAT Q/Q Growth		 0.00% 0.00% -18.93% -4.92% 0.02% 14.25% 10.54%
Net Income Q/Q Growth		 0.00% 0.00% -24.51% -4.06% 0.50% 14.72% 7.88%
EPS Q/Q Growth		 0.00% 0.00% 46.92% -0.37% 3.01% 14.79% 12.17%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -12.56% -3.90% -5.66% 15.44% 15.54%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 1.64% -6.83% 21.28% 18.34%
Invested Capital Q/Q Growth		 0.00% 0.00% 13.02% 0.90% 12.41% -3.68% -9.48%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 -559.23% -7,149.88% -38,043.60% 0.00% 0.00% -656.55% -3,003.85%
Operating Margin		 -543.62% -7,016.08% -38,576.00% 0.00% 0.00% -672.21% -2,965.25%
EBIT Margin		 -575.77% -7,384.85% -38,575.60% 0.00% 0.00% -664.95% -3,022.50%
Profit (Net Income) Margin		 -574.13% -8,357.34% -38,160.80% 0.00% 0.00% -634.33% -2,980.35%
Tax Burden Percent		 94.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 105.02% 113.17% 98.92% 98.48% 95.14% 95.39% 98.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -17.08% -45.34% -54.44% -98.37% -164.30% 543.76%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -12.93% -38.63% 0.00% 0.00% -85.01% -182.49%
Return on Assets (ROA)		 0.00% -14.64% -38.21% 0.00% 0.00% -81.10% -179.95%
Return on Common Equity (ROCE)		 0.00% -17.07% -45.34% -54.44% -98.37% -164.30% 543.76%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -17.08% -45.25% -59.05% -174.70% -489.14% 0.00%
Net Operating Profit after Tax (NOPAT)		 -20 -21 -68 -76 -91 -52 -42
NOPAT Margin		 -380.53% -4,911.26% -27,003.20% 0.00% 0.00% -470.55% -2,075.68%
Net Nonoperating Expense Percent (NNEP)		 0.00% -12.43% -11.55% -13.37% -19.99% -22.45% -64.43%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -128.45% -362.85% 114.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 145.17% 2,469.70% 15,366.40% 0.00% 0.00% 198.62% 886.60%
R&D to Revenue		 498.44% 4,646.39% 23,309.60% 0.00% 0.00% 573.59% 2,178.65%
Operating Expenses to Revenue		 643.62% 7,116.08% 38,676.00% 0.00% 0.00% 772.21% 3,065.25%
Earnings before Interest and Taxes (EBIT)		 -30 -32 -96 -108 -130 -73 -60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -31 -95 -107 -129 -72 -60
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.70 3.43 1.72 1.67 2.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 1.70 3.43 1.72 1.67 2.00 0.00
Price to Revenue (P/Rev)		 36.35 832.41 2,892.35 0.00 0.00 2.60 16.69
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 277.81 1,912.43 0.00 0.00 0.00 13.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 17.32 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.13 -1.15 -1.18 -1.30 -1.89 2.56
Leverage Ratio		 0.00 1.17 1.19 1.23 1.38 2.03 -3.02
Compound Leverage Factor		 0.00 1.32 1.17 1.21 1.31 1.93 -2.98
Debt to Total Capital		 0.00% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 99.67% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.02 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 7.76 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.02 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 11.29 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 6.20 8.75 1.75 -6.12 -16.09 -70.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 7.46 12.48 9.53 4.11 3.52 0.37
Quick Ratio		 0.00 7.40 12.36 9.32 3.93 3.37 0.32
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 6.88 -61 -75 -85 -58 -33
Operating Cash Flow to CapEx		 -639.17% -6,158.31% -6,733.12% -34,120.75% -106,137.76% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 1.61 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -5.92 -8.51 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -6.84 -8.64 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.13 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.10 0.06 0.00 0.00 9.64 5.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -28 -34 -35 -41 -35 -43
Invested Capital Turnover		 0.00 -0.03 -0.01 0.00 0.00 -0.29 -0.05
Increase / (Decrease) in Invested Capital		 0.00 -28 -6.21 -1.01 -5.63 6.02 -8.53
Enterprise Value (EV)		 0.00 119 478 95 6.45 -20 26
Market Capitalization		 189 357 723 310 118 29 33
Book Value per Share		 $0.00 $24.91 $5.72 $4.80 $1.47 $0.30 ($0.62)
Tangible Book Value per Share		 $0.00 $24.91 $5.72 $4.80 $1.47 $0.30 ($0.62)
Total Capital		 0.00 211 211 180 71 14 -36
Total Debt		 0.00 0.68 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.68 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -238 -245 -216 -111 -49 -7.12
Capital Expenditures (CapEx)		 1.51 0.59 0.92 0.27 0.10 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -30 -18 -18 -23 -12 -21
Debt-free Net Working Capital (DFNWC)		 0.00 208 227 197 88 37 -14
Net Working Capital (NWC)		 0.00 208 227 197 88 37 -14
Net Nonoperating Expense (NNE)		 10 15 28 31 33 18 18
Net Nonoperating Obligations (NNO)		 0.00 -238 -245 -216 -111 -49 -7.12
Total Depreciation and Amortization (D&A)		 0.86 1.01 1.33 1.20 1.22 0.93 0.37
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -7,036.13% -7,000.00% 0.00% 0.00% -112.31% -1,051.35%
Debt-free Net Working Capital to Revenue		 0.00% 48,582.75% 90,991.60% 0.00% 0.00% 333.56% -695.45%
Net Working Capital to Revenue		 0.00% 48,582.75% 90,991.60% 0.00% 0.00% 333.56% -695.45%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.76) ($2.74) ($2.58) ($1.44) ($50.50)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 37.32M 38.93M 47.78M 48.57M 1.18M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.76) ($2.74) ($2.58) ($1.44) ($50.50)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 37.32M 38.93M 47.78M 48.57M 1.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.76) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 34.56M 47.61M 48.10M 58.40M 1.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -21 -68 -76 -91 -52 -42
Normalized NOPAT Margin		 -380.53% -4,911.26% -27,003.20% 0.00% 0.00% -470.55% -2,075.68%
Pre Tax Income Margin		 -604.65% -8,357.34% -38,160.80% 0.00% 0.00% -634.33% -2,980.35%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -18.37 -7.42 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -12.14 -4.93 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -19.29 -7.55 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -13.07 -5.07 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 -0.02% -0.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.02% -0.05% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioAtla

This table displays calculated financial ratios and metrics derived from BioAtla's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 47,803,306.00 47,935,808.00 48,096,717.00 48,115,918.00 48,335,737.00 - 58,401,147.00 58,418,142.00 58,721,588.00 58,792,088.00 82,846,317.00
DEI Adjusted Shares Outstanding		 47,803,306.00 47,935,808.00 48,096,717.00 48,115,918.00 48,335,737.00 - 1,168,023.00 58,418,142.00 58,721,588.00 1,175,842.00 1,656,926.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.70 -0.56 -0.48 -0.44 -0.22 - -13.13 -0.32 -0.27 -8.32 -3.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Growth		 -34.59% 1.17% 15.46% 41.11% 68.24% 46.05% 35.78% 13.40% -43.46% 35.27% 59.98%
EBIT Growth		 -34.07% 0.92% 15.49% 40.95% 67.83% 45.95% 35.67% 13.78% -41.05% 36.11% 59.68%
NOPAT Growth		 -33.77% 0.08% 15.46% 40.94% 67.82% 43.08% 27.98% 15.13% -22.35% 43.03% 47.16%
Net Income Growth		 -29.27% 2.24% 15.39% 41.06% 68.23% 44.72% 34.00% 11.20% -49.05% 34.27% 58.63%
EPS Growth		 -1.45% 12.70% 17.24% 41.33% 68.57% 45.45% 34.00% 27.27% -22.73% 46.67% 58.63%
Operating Cash Flow Growth		 -13.86% -22.90% -36.08% 20.34% 81.23% 43.91% 47.16% 26.43% -92.54% 52.84% 67.66%
Free Cash Flow Firm Growth		 39.30% 24.43% -68.08% -52.41% -55.88% -21.23% 49.13% 71.32% 82.58% 111.77% 108.21%
Invested Capital Growth		 -31.26% -16.01% 14.74% 31.43% 27.98% 14.75% -2.92% -15.38% -17.91% -24.51% -23.43%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 5.78% 18.95% 14.11% 10.22% 49.18% -37.65% -2.24% -21.08% 15.81% 37.89% 36.78%
EBIT Q/Q Growth		 5.79% 18.53% 14.38% 10.16% 48.67% -36.89% -1.92% -20.40% 16.03% 37.99% 35.69%
NOPAT Q/Q Growth		 5.86% 18.52% 14.29% 10.16% 48.71% -44.13% -8.43% -5.86% 26.05% 32.88% -0.57%
Net Income Q/Q Growth		 6.79% 19.20% 13.71% 9.31% 49.76% -40.60% -3.02% -22.02% 15.68% 37.99% 35.16%
EPS Q/Q Growth		 6.67% 21.43% 12.73% 8.33% 50.00% -36.36% -3.02% -23.08% 15.63% 40.74% 35.16%
Operating Cash Flow Q/Q Growth		 -13.49% -9.42% -3.03% 37.74% 73.26% -227.03% 2.95% 13.31% 30.02% 19.90% 33.46%
Free Cash Flow Firm Q/Q Growth		 30.11% -6.88% -56.62% -30.27% 28.52% 16.88% 34.28% 26.56% 56.59% 156.20% -54.17%
Invested Capital Q/Q Growth		 -5.44% 12.41% 24.23% 2.01% -10.75% -3.68% 8.52% -9.86% -13.18% -9.48% 9.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -100.45% 0.00% 0.00% 0.00% 0.00% -492.25% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -102.45% 0.00% 0.00% 0.00% 0.00% -462.75% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -102.53% 0.00% 0.00% 0.00% 0.00% -493.20% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -96.24% 0.00% 0.00% 0.00% 0.00% -489.20% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.02% 99.97% 100.59%
Interest Burden Percent		 95.05% 94.27% 95.00% 95.90% 93.86% 96.41% 97.46% 98.77% 99.16% 99.22% 99.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -104.56% -98.37% -115.68% -134.14% -139.06% -164.30% -246.21% -813.88% 1,565.05% 543.76% 275.38%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -10.56% 0.00% 0.00% 0.00% 0.00% -29.78% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -9.91% 0.00% 0.00% 0.00% 0.00% -29.54% 0.00%
Return on Common Equity (ROCE)		 -104.56% -98.37% -115.68% -134.14% -139.06% -164.30% -246.21% -813.88% 1,565.05% 543.76% 275.38%
Return on Equity Simple (ROE_SIMPLE)		 -131.02% 0.00% -239.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -20 -17 -15 -7.89 -11 -12 -13 -9.65 -6.48 -6.52
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -71.72% 0.00% 0.00% 0.00% 0.00% -323.93% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.52% -4.25% -4.47% -4.94% -2.73% -4.38% -5.32% -14.17% -18.90% -11.77% 1.00%
Return On Investment Capital (ROIC_SIMPLE)		 - -28.26% -34.44% -49.03% -34.35% -79.71% -2,254.08% 77.95% 30.90% 17.90% 17.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 53.41% 0.00% 0.00% 0.00% 0.00% 163.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 149.05% 0.00% 0.00% 0.00% 0.00% 399.75% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 202.45% 0.00% 0.00% 0.00% 0.00% 562.75% 0.00%
Earnings before Interest and Taxes (EBIT)		 -35 -29 -24 -22 -11 -15 -16 -19 -16 -9.86 -6.34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -35 -28 -24 -22 -11 -15 -16 -19 -16 -9.85 -6.22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.86 1.67 3.33 2.10 3.70 2.00 37.03 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.86 1.67 3.33 2.10 3.70 2.00 37.03 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 7.73 2.60 1.84 2.10 0.00 16.69 6.67
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 2.60 0.00 0.00 0.45 0.00 13.13 5.69
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.35 -1.30 -1.33 -1.48 -1.68 -1.89 -2.25 -5.46 7.84 2.56 0.93
Leverage Ratio		 1.43 1.38 1.43 1.59 1.82 2.03 2.54 6.55 -9.45 -3.02 -1.27
Compound Leverage Factor		 1.36 1.30 1.35 1.53 1.70 1.95 2.47 6.47 -9.37 -3.00 -1.27
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.62 -3.33 -4.39 -8.53 -8.93 -12.45 -18.40 -28.24 -50.57 -58.26 -94.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.14 4.11 4.49 3.81 3.11 3.52 2.35 1.24 0.54 0.37 0.15
Quick Ratio		 3.97 3.93 4.19 3.53 2.90 3.37 2.02 1.10 0.46 0.32 0.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 -14 -22 -29 -21 -17 -11 -8.39 -3.64 2.05 0.94
Operating Cash Flow to CapEx		 -109,380.00% -374,025.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.10 0.13 0.17 0.23 0.00 0.06 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 7.66 9.64 11.84 14.53 0.00 5.01 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -47 -41 -31 -30 -34 -35 -32 -35 -40 -43 -39
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.27 -0.29 -0.35 -0.34 0.00 -0.05 -0.06
Increase / (Decrease) in Invested Capital		 -11 -5.63 5.35 14 13 6.02 -0.90 -4.66 -6.01 -8.53 -7.45
Enterprise Value (EV)		 -60 6.45 85 4.26 29 -20 -12 4.93 32 26 11
Market Capitalization		 81 118 165 66 85 29 20 23 40 33 13
Book Value per Share		 $1.98 $1.47 $1.03 $0.65 $0.48 $0.30 $0.01 ($0.29) ($0.53) ($0.62) ($0.63)
Tangible Book Value per Share		 $1.98 $1.47 $1.03 $0.65 $0.48 $0.30 $0.01 ($0.29) ($0.53) ($0.62) ($0.63)
Total Capital		 95 71 50 31 23 14 0.55 -17 -31 -36 -37
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -141 -111 -81 -62 -57 -49 -32 -18 -8.32 -7.12 -1.96
Capital Expenditures (CapEx)		 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -23 -13 -13 -15 -12 -11 -14 -17 -21 -20
Debt-free Net Working Capital (DFNWC)		 112 88 67 49 41 37 22 4.01 -8.31 -14 -18
Net Working Capital (NWC)		 112 88 67 49 41 37 22 4.01 -8.31 -14 -18
Net Nonoperating Expense (NNE)		 8.81 6.95 6.11 5.69 2.70 3.51 3.00 5.66 6.13 3.31 -0.17
Net Nonoperating Obligations (NNO)		 -141 -111 -81 -62 -57 -49 -32 -18 -8.32 -7.12 -1.96
Total Depreciation and Amortization (D&A)		 0.27 0.37 0.24 0.23 0.23 0.23 0.18 0.12 0.06 0.02 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -140.10% -112.31% -98.47% -129.04% 0.00% -1,051.35% -978.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 373.68% 333.56% 195.74% 36.48% 0.00% -695.45% -879.95%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 373.68% 333.56% 195.74% 36.48% 0.00% -695.45% -879.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.70) ($0.55) ($0.48) ($0.44) ($0.22) ($0.30) ($13.00) ($0.32) ($0.27) ($8.00) ($4.22)
Adjusted Weighted Average Basic Shares Outstanding		 47.83M 47.78M 48.09M 48.21M 48.34M 48.57M 1.16M 58.50M 58.75M 1.18M 1.50M
Adjusted Diluted Earnings per Share		 ($0.70) ($0.55) ($0.48) ($0.44) ($0.22) ($0.30) ($13.00) ($0.32) ($0.27) ($8.00) ($4.22)
Adjusted Weighted Average Diluted Shares Outstanding		 47.83M 47.78M 48.09M 48.21M 48.34M 48.57M 1.16M 58.50M 58.75M 1.18M 1.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 47.94M 48.10M 48.12M 48.34M 48.35M 58.40M 1.17M 58.72M 58.79M 1.66M 1.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -20 -17 -15 -7.89 -11 -12 -13 -9.65 -6.48 -6.52
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -71.72% 0.00% 0.00% 0.00% 0.00% -323.93% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -96.24% 0.00% 0.00% 0.00% 0.00% -489.35% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

BioAtla’s latest quarter shows a company still in heavy cash-burn mode, with no revenue and a very large loss, but also with a balance sheet that has been rebuilt over the last year through financing activity. In Q1 2026, BioAtla reported zero revenue, a net loss of $6.3 million, and operating cash outflow of $5.3 million. The company ended the quarter with just $2.0 million in cash and equivalents, while liabilities remained high at $45.9 million.

  • Cash rose from $1.2 million at the end of Q4 2025 to $2.0 million in Q1 2026, helped by financing activity.
  • The company generated $296.4 million of other income in Q1 2026, which significantly offset operating losses on the income statement.
  • Quarterly operating cash burn improved versus Q4 2025, with cash used in operations narrowing to $5.3 million from $7.9 million.
  • Research and development expense fell sharply to $4.6 million in Q1 2026 from $8.0 million in Q4 2025, showing a meaningful reduction in spending.
  • The company reduced debt repayments to $289,000 in Q1 2026, and financing activity was positive for the quarter.
  • Revenue remained at $0 in Q1 2026, so the business still has no recurring product sales to support operations.
  • Operating expenses totaled $9.3 million, led by $4.7 million of SG&A and $4.6 million of R&D, keeping the company firmly unprofitable.
  • BioAtla reported negative equity of $37.3 million at quarter-end, which is a sign of accumulated losses and a weak balance-sheet position.
  • Accounts payable were $19.1 million, far above cash on hand, suggesting meaningful near-term liquidity pressure.
  • Over the past year, cash has fallen dramatically from $80.6 million in Q1 2024 to $2.0 million in Q1 2026, highlighting a steep deterioration in liquidity.

Trends over the last four years show a company that has progressively burned through cash while continuing to fund R&D. Quarterly cash balances fell from $141.3 million in Q3 2023 to $2.0 million in Q1 2026. Losses have also remained large, with quarterly net losses generally in the $10 million to $33 million range over the last several years, before improving to $6.3 million in the latest quarter. On the positive side, share count has come down from the very high levels seen in late 2025, but BioAtla is still dependent on external financing and non-operating income to stay afloat.

Bottom line: BioAtla’s latest quarter shows some improvement in spending and operating cash burn, but the company still lacks revenue, has negative equity, and has very limited cash relative to its liabilities. For retail investors, this remains a high-risk, financing-dependent biotech story.

07/20/26 12:12 PM ETAI Generated. May Contain Errors.

BioAtla Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioAtla's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

BioAtla's net income appears to be on an upward trend, with a most recent value of -$59.61 million in 2025, rising from -$29.86 million in 2019. The previous period was -$69.78 million in 2024. Find out what analysts predict for BioAtla in the coming months.

BioAtla's total operating income in 2025 was -$59.31 million, based on the following breakdown:
  • Total Gross Profit: $2 million
  • Total Operating Expenses: $61.31 million

Over the last 6 years, BioAtla's total revenue changed from $5.20 million in 2019 to $2 million in 2025, a change of -61.5%.

BioAtla's total liabilities were at $50.02 million at the end of 2025, a 31.1% increase from 2024, and a 43.1% increase since 2020.

In the past 5 years, BioAtla's cash and equivalents has ranged from $7.12 million in 2025 to $244.98 million in 2021, and is currently $7.12 million as of their latest financial filing in 2025.

Over the last 6 years, BioAtla's book value per share changed from 0.00 in 2019 to -0.62 in 2025, a change of -61.6%.


Related Companies

Financial statements for NASDAQ:BCAB last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
The gold strategy buried in Trump's plans that insiders are already watching
Nancy Pelosi's portfolio gained 71 percent in 2024 while the S&P 500 returned just 28 percent. In 2023, she ea...
American Alternative | Sponsoredtc pixel
SMX: From Under-the-Radar to Must-Watch!
SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...
Smallcaps Daily | Sponsoredtc pixel
This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...
Base Camp Trading | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel